Heart Valve Technology

This channel includes news and new device innovations about heart valve technologies, including the aortic valve, mitral valve, pulmonic valve, and tricuspid valve. This includes information on transcatheter valve technologies like transcatheter aortic valve replacement (TAVR, or implantation TAVI), transcatheter mitral valve repair or replacement (TMVR), transcatheter and surgical valve repairs, and surgical replacement valves. Newer devices are now being used for transcatheter tricuspid valve repair replacement (TTVR). 

RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News
Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial ...

Home November 18, 2020
Home
Feature | Heart Valve Technology
TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

Home November 17, 2020
Home
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | Dave Fornell, Editor
Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

Home November 17, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor
Top 10 Takeaways on Interventional Technologies at TCT 2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Videos | Heart Valve Technology
VIDEO: Results Mixed on Use of Cerebral Embolic Protection in TAVR From the STS/ACC TVT Registry

David Cohen, M.D., presents late-breaking data from the STS/ACC Transcatheter Valve Registry (TVT) showing the impact of ...

Home October 19, 2020
Home
Videos | Heart Valve Technology
VIDEO: General vs Local Anesthesia for TAVR Addressed in SOLVE-TAVI Trial

Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local ...

Home October 19, 2020
Home
Videos | Heart Failure
VIDEO: Use of MitraClip as a Bridge to Heart Transplant

The late-breaking MitraBridge Study was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2020 meeting showed ...

Home October 16, 2020
Home
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect
News | Heart Valve Technology
Keystone Heart TAVR Embolic Protection Device Did Not Demonstrate Superiority 

October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart ...

Home October 15, 2020
Home
The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020. #TCT #TCT2020 #TCTconnect
Feature | Heart Valve Technology
Acurate neo TAVR Valve Fails to Meet Noninferiority With Medtronic CoreValve Evolut

October 15, 2020 – The SCOPE II trial comparing the Boston Scientific Acurate neo vs. Medtronic CoreValve Evolut TAVR ...

Home October 15, 2020
Home
An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture. #TCT2020 #TCTconnect
News | Heart Valve Technology
Transcatheter Closure of Residual ASD After Transcatheter Mitral Valve Repair Was Not Superior to Medical Therapy

October 15, 2020 – The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial ...

Home October 15, 2020
Home
Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). 
News | Heart Valve Technology
Medtronic Launches Head-to-Head TAVR Study Comparing the Corevalve Evolut vs Edwards Sapien in Small Annulus Patients

October 14, 2020 — Medtronic announced it is starting a randomized, head-to-head study comparing two transcatheter ...

Home October 14, 2020
Home
Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.
Feature | Udi Nussinovitch M.D., Ph.D.
What is New in Cardiology? A Review of All Major Emerging Technologies for Heart Diseases

This is an overview of some of the biggest cardiology technology advances. These innovations are covered in more detail ...

Home October 09, 2020
Home
The Cardiac Dimensions Carillon Mitral Contour System, a transcatheter device used to treat functional mitral regurgitation (FMR) in patients with heart failure.
News | Heart Valve Technology
Cardiac Dimensions Announces $17.5 Million in Financing to Accelerate Sales Expansion of The Carillon Mitral Contour System

October 2, 2020 — Cardiac Dimensions announced the company has closed a $17.5 million Series C financing that will be ...

Home October 02, 2020
Home
Boston Scientific launched the Acurate neo2 transcatheter aortic valve replacement (TAVR) system in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original Acurate neo platform. Compared to the previous generation device, the Acurate neo2 valve system also has an expanded indication for patients with aortic stenosis. #TAVR #TAVI
News | Heart Valve Technology
Boston Scientific Launches Acurate neo2 Transcatheter Aortic Valve System in Europe

September 29, 2020 — Boston Scientific launched the Acurate neo2 transcatheter aortic valve replacement (TAVR) system in ...

Home September 29, 2020
Home
The VitalPatch RTM biosensor is being used in the TELESTAR-TAVR clinical study (Deployment of Telemedicine for Symptom Tracking And Decrease Readmission Rate in TAVR Patients). It will evaluate patients who undergo a transcatheter aortic valve replacement (TAVR) and monitor them following the procedure utilizing the latest technology from VitalConnect, VistaSolution LIVE. 
News | Wearables
VitalConnect Announces Initiation of TELESTAR-TAVR Clinical Study

September 25, 2020 — Remote and in-hospital wearable biosensor technology company VitalConnect Inc. has started the ...

Home September 25, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now